EP0498920B1 - Testverfahren zum Nachweis der Anwesenheit von Bakterien - Google Patents

Testverfahren zum Nachweis der Anwesenheit von Bakterien Download PDF

Info

Publication number
EP0498920B1
EP0498920B1 EP91107960A EP91107960A EP0498920B1 EP 0498920 B1 EP0498920 B1 EP 0498920B1 EP 91107960 A EP91107960 A EP 91107960A EP 91107960 A EP91107960 A EP 91107960A EP 0498920 B1 EP0498920 B1 EP 0498920B1
Authority
EP
European Patent Office
Prior art keywords
bacteria
membrane
antibodies
colonies
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP91107960A
Other languages
English (en)
French (fr)
Other versions
EP0498920A2 (de
EP0498920A3 (en
Inventor
Thomas L. Benjamin
Joan Chen-Wu
Thomsen Hansen
Barbara Jackson
David Livingstone
Steven Tannenbaum
Gerald Wogan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vicam LP
Original Assignee
Vicam LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicam LP filed Critical Vicam LP
Publication of EP0498920A2 publication Critical patent/EP0498920A2/de
Publication of EP0498920A3 publication Critical patent/EP0498920A3/en
Application granted granted Critical
Publication of EP0498920B1 publication Critical patent/EP0498920B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria

Definitions

  • This invention relates to an assay method for quickly and easily detecting the presence of bacteria.
  • an immunoassay method is utilized to detect the presence of viable bacteria strains in foods and other potentially contaminated samples using an assay characterized by 1) capture of specific bacterial cells with specific antibodies; (2) incubation of the captured cells to form bacteria colonies; (3) imprint of the colonies to a colony lift membrane; and (4) immunochemical detection and species identification of the colonies on the colony lift membrane.
  • bacterial pathogens are well recognized cause of severe illness, so that there is an ever present need for the detection of such pathogens in both clinical specimens (i.e. blood, tissue, urine and other body extracts and fluids), agricultural specimens (such as food products) and environmental specimens (such as surfaces in food processing plants).
  • clinical specimens i.e. blood, tissue, urine and other body extracts and fluids
  • agricultural specimens such as food products
  • environmental specimens such as surfaces in food processing plants
  • Antibodies to an antigen present in the bacteria of interest are generally used in these methods in some form of a two site assay. That is, one antibody is immobilized and acts to capture the target bacterial antigens. This allows for separation of the target antigen from the food sample.
  • a second antibody to this antigen (having the same or a different epitope) is labeled in some fashion such as radioactively with 125 I or enzymatically with horse radish peroxidase, and when added to the immobilized antibody antigen complex also becomes immobilized. Subsequent steps remove unbound labeled antibody.
  • the label left attached is measured and usually compared against standards (positive and negative controls) to determine the presence of the target bacteria.
  • At least one of the two antibodies used in the two site assay must be specific to the target bacteria.
  • This type of immunoassay is known as a direct assay.
  • Other forms, such as the competition assay are also used but tend to be less sensitive, and technically more difficult to perform.
  • Immunoassays are described in Skjerve, E. et al. Applied and Environmental Microbiology, Vol 56, No. 11 (1990), 3478 to 3481 and in WO 89/01162. Skjerve et al. describe a method for detection of Listeria in foods by immunomagnetic separation.
  • the detection of the bacteria captured on the immunomagnetic beads is by spreading the beads on agar and visually detecting the colonies.
  • the document reports a sensitivity of detection of 100 to 200 bacterial cells per ml.
  • WO 89/01162 describes a method for detecting microorganisms in a sample, comprising exposing the sample to a solid support to which antibodies specific for the organism are adsorbed and growing the bound organism to a detectable level followed by immunoassay or releasing the organism from the support and growing them to visually detectable colonies.
  • one object of the invention is to provide an assay procedure for rapid and easy identification of the presence of a particular bacteria of interest in a sample.
  • the assay procedure is applicable to the detection of bacteria, but may also be applied to the detection of molds and yeast which are not included within the present invention.
  • Of particular importance is the detection of the presence of potentially harmful contaminants, particularly those which cannot be visually detected by eye.
  • a broad range of contaminants can be detected by the assay, so long as the contaminant can be cultured to form colonies and antibodies can be raised against the contaminant.
  • the assay is used to detect various bacteria, and can be utilized to detect the presence of any specific, selected bacteria of interest.
  • the bacteria can be either pathogenic or non-pathogenic, although the invention is particularly important for detection of potentially contaminating pathogenic bacteria.
  • Specific bacteria detectable by the assay of the invention include, for example, Listeria, Campylobacter, Escherichia coli, Salmonella, Clostridia (such as Clostridium botulinum and Clostridium perfingens), Shigella, Staphylococci (such as Stapylococcus aureus), Vibrio (such as Vibrio vulnificus, Vibrio cholerae and Vibrio parahaemolyticus), Yersinia (such as Yersinia enterocolitica and Yersinia pseudotuberculosis) Plesiomonas shigelloides, Bacilli (such as Bacillus cereus) and Aeromonas (such as Aeromonas hydrophil
  • various molds can be detected, including Byssochlamys, Fusarium, Geotrichum, Penicillium and Scopulariopsis and various yeasts can be detected, such as Kluyveromyces, Pichia, Saccharomyces, Candida and Rhodotorula, but are not subject of the present invention.
  • the method of the invention therefore, generally comprises the following procedural steps:
  • the method of the invention is particularly characterized by the use of an antibody/s to first select out bacteria from a sample.
  • the antibody/s used for this step need not be totally specific to the bacteria of interest as subsequent selective and specific steps combine to confer the ultimate specificity of the assay for only specific bacteria of interest.
  • Further uniquely characterizing the method of the invention is the use of a colony lift membrane and subsequent detection steps. Using these characteristic features, the method of the invention can be importantly applied to the rapid and specific detection of viable strains of bacteria, particularly detection by a simple visual means, detectable by the human eye.
  • the assay particularly provides a very sensitive assay detection, capable of detecting 1 colony forming unit (CFU) per 25 ml of sample.
  • the assay of the invention can be utilized to detect the presence of bacteria in a wide variety of samples, both solid and liquid, including food, agricultural products, environmental samples and various clinical specimens. If the sample is liquid, it can be per se subjected to the procedure of the invention, or first diluted, or concentrated by centrifugation. On the other hand, if the sample is solid, it should be first liquified (for example in water) using standard known techniques, such as by use of a blender/storaum. The liquid or liquified sample may, if desired, be filtered through a course paper, glass or other matrix filter to remove particulates. If the sample to be tested is an environmental sample, then swabs or scrapings of the tested surface or material are mixed in a collection buffer and then treated as a liquified food sample.
  • Immobilized antibodies to target bacterial cells are used to separate the bacteria cells from the sample.
  • one or more antibodies may be used to recognize all target strains of the bacteria genus of interest.
  • the antibodies used in this step recognize bacteria cell surface antigens, and these antibodies are preferably immobilized on the microspheres which can be mixed with the sample and separated from the sample mixture in some manner subsequent to capture of the target bacterial cells.
  • the microspheres used as the immobilizing matrix are magnetic beads. After an incubation period in which the liquid sample or liquified sample is mixed with the magnetic beads having antibodies attached, the antibody bound particles and attached bacteria are then separated from the sample by means of a magnetic field (magnetic capture) and washed to remove other potential impurities.
  • any class of antibodies can be used (including IgG and IgM) and either polyclonal antibodies or monoclonal antibodies can be used depending upon various factors, including the degree of sensitivity desired.
  • polyclonal antibodies can be prepared according to per se known procedures. For example, procedures such as those described by Hurn, B.A. et al. (1980) in Meth. in Enzymology, Ed. Van Vanakis, H. and Langone, J., pp. 104-142, can be used.
  • monoclonal antibodies are prepared using the method originally authored by Milstein and Köhler and published in Nature (1975), 256, pps. 495-497.
  • the basic process involves injecting an animal, usually a mouse, with an immunogenic substance. After suitable time for antibody production to the immunogen, the mouse is sacrificed. Cells are removed from the spleen and fused with myeloma cells. Hybridoma cells resulting from this fusion are able to reproduce in vitro , and each expresses genetic information for one specific antibody.
  • the antibodies produced from one hybridoma fusion thus will only recognize a single antigenic determinant of the immunogen.
  • Cells cultured from individual hybridoma cells are screened for production of antibodies to the target antigenic determinant. Those hybridomas positive for the target antigen are further screened to identify those having any affinity.
  • the monoclonal antibodies used in the present invention should have an affinity of at least 10 8 liters/mole. Monoclonal antibodies displaying all of these characteristics are then screened using actual assay conditions to determine if the assay condition alters the antibody binding characteristics or affinity, and to screen out those with cross reactivity to possible contaminating antigens.
  • the antibodies are immobilized on magnetic beads. This can be accomplished by procedures which are per se known, such as those described in U.S. Patent No. 3,970,518; No. 4,018,886, No. 4,855,045 and No. 4,230,685.
  • attachment of antibodies to magnetic particles is accomplished through a Protein A intermediate. That is, Protein A is first attached to the magnetic particles and the antibodies of choice are then bound to the Protein A. The use of the Protein A intermediate greatly increases the effectiveness of capture by the attached antibodies. (Forsgren et al. (1977) J. Immunol. 99:19) Protein A attaches to the Fc portion of IgG subclass antibodies, thus extending and presenting the Fab portion of these antibodies. The resulting correct orientation of the antibodies and extension away from the particles leads to a very effective interaction between the bound antibodies and their target.
  • the method of attachment of Protein A to magnetic particles may proceed by any of several processes available through the scientific literature.
  • magnetic iron oxide particles of approximately 1 micrometer diameter are chemically derivatized by reaction, first with 3-aminopropyltriethoxysilane, then with glutaraldehyde.
  • the derivatized magnetic particles are then mixed with Protein A resulting in a magnetic particle to which Protein A is covalently attached.
  • the antibodies are then added to the Protein A magnetic particles and after a short incubation the protein A-antibody complexes form. (Weetall, H.H. (1976) Meth. in Enzymol. 44:134-148)
  • These derivatized particles with Protein A-antibodies attached are now ready for use in bacterial cell capture.
  • the captured and immobilized bacterial cells are placed on a medium on which the cells will grow and are incubated. Incubation is conducted for a time sufficient to form bacterial colonies visible to the eye.
  • Particular media for incubation depend, of course, upon the bacteria of interest to be detected.
  • Such mediums, preferably solid, are per se known to those skilled in the art for various bacteria, as disclosed, for example, in T. Maniatis et al., Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Lab. 1982.
  • Incubation times and conditions are also varied and per se known, depending upon the particular bacteria of interest. Generally, sufficient growth is accomplished within 6 to 24 hours.
  • Colony lift membranes are per se known and may be comprised of, for example, nitrocellulose or nylon.
  • the membrane is preferably cut to the size of the container or dish containing the growth medium, so that all colonies growing on the container are overlayed with the same single sheet. In this manner, the sheet/membrane acquires the same pattern of colonies that was originally contained on the growth medium.
  • the growth medium can be maintained and utilized for multiple colony lifts from the same plate, and the lift membranes can be utilized to replicate the same colonies onto additional growth medium plates ("replica plating").
  • Step 5 Fixing of the Colonies to the Lift Membrane
  • Suitable fixing treatments include placing the lift membrane in a solution of methanol and placing the membrane in a solution of the detergent sodium dodecyl sulfate with brief heating to 70°C.
  • Suitable blocking agents include, for example, caseine and BSA.
  • the lift membrane having fixed thereto the colony material from the bacterial colonies is next contacted with antibodies specific to the bacteria of interest.
  • antibodies specific to the bacteria of interest either polyclonal or monoclonal antibodies can be utilized, but in either case have affinity for the particular bacteria to be detected. These antibodies, when contacted with the lift membrane, will adhere/bind to material from the specific target bacteria colonies, but will not bind to the other colonies.
  • Useful polyclonal antibodies include, for example, those from Difo poly sera raised in rabbits. These antibodies can also be specific for particular strains to be detected.
  • Listeria monocytogenes includes strains SV 1/2b, 1/2c, 3a, 3b, 3c, 4a, 4a/b, 4b, 4c, 4d, 4e, 7, with strains SV 1/2a, 1/2b and 4b being the most common pathogenic strains. It is useful, therefore, to detect the presence in a sample of pathogenic Listeria by utilizing a polyclonal seria against Listeria serovars 1/2 and 4.
  • the membrane sheet is washed to remove any antibody which is not specifically bound to material from the bacteria colonies of interest.
  • Treatment Step 6 with a first antibody specific to the bacteria cells of interest provides the first step for selection and identification of the specific bacteria of interest.
  • the membrane sheet is then contacted with a second antibody.
  • this antibody may be either polyclonal or monoclonal, but importantly is (a) capable of binding to the first antibody and (b) labeled in a manner to enable subsequent detection.
  • the second antibody is an anti-rabbit IgG/label conjugate. If the first antibody is, for example, the above-noted Difco poly sera, then the second antibody is an anti-rabbit IgG/label conjugate. If the first antibody is a monoclonal antibody derived from mouse, than the second antibody is an anti-mouse IgG/label conjugate.
  • the antibody utilized in Step 6 can itself be a labeled antibody.
  • the assay can then proceed to detection of the label (Step 8) without the need for use of a second antibody.
  • Direct labels may include fluorescent, chemiluminescent, bioluminescent, radioactive, metallic, biotin or enzymatic molecules.
  • Methods of combining these labels to antibodies or other macromolecules are well known to those in the art. Examples include the methods of Hijmans, W. et al. (1969), Clin. Exp. Immunol. 4 , 457-, for fluorescein isothiocyanate, the method of Goding, J.W. (1976), J. Immunol. Meth. 13 , 215-, for tetramethylrhodamine isothiocyanate, and the method of Ingrall, E. (1980), Meth. in Enzymol. 70 , 419-439 for enzymes.
  • detector antibodies may also be labeled indirectly.
  • the actual detection molecule is attached to a secondary antibody or other molecule with binding affinity for the anti-bacteria cell surface antibody.
  • a secondary antibody is used it is preferably a general antibody to a class of antibody from the animal species used to raise the anti-bacteria cell surface antibodies.
  • the second antibody may be conjugated to an enzyme, either alkaline phosphatase or to peroxidase.
  • an enzyme either alkaline phosphatase or to peroxidase.
  • the membrane sheet is immersed in a solution containing a chromogenic substrate for either alkaline phosphatase or peroxidase.
  • a chromogenic substrate is a compound which can be cleaved by an enzyme to result in the production of some type of detectable signal which only appears when the substrate is cleaved from the base molecule.
  • the chromogenic substrate is colorless, until it reacts with the enzyme, at which time an intensely colored product is made.
  • detection molecules include fluorescent substances, such as 4-methylumbelliferyl phosphate, and chromogenic substances, such as 4-nitrophenylphosphate, 3,3',5,5'-tetramethylbenzidine and 2,2'-azino-di-[3-ethelbenz-thiazoliane sulfonate (6)].
  • alkaline phosphatase and peroxidase include ⁇ -galactosidase, ⁇ -glucuronidase, ⁇ -glucosidase, ⁇ -glucosidase, ⁇ -mannosidase, galactoseoxidase, glucose oxidase and hexokinase.
  • the following is a specific example to show the use of the assay of the invention to particularly detect the presence of Listeria, Salmonella or E. coli.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Claims (14)

  1. Verfahren zum Nachweis der Gegenwart von Bakterien, das folgende Schritte umfaßt:
    (a) Zusammenbringen einer Probe, die auf das Vorhandensein von ausgewählten Bakterien zu testen ist, mit magnetischen Kügelchen, auf denen Erstantikörper gegen die ausgewählten Bakterien immobilisiert sind;
    (b) Inkubation der Probe und der magnetischen Kügelchen, auf denen die Antikörper immobilisiert sind, um dadurch die Zellen der ausgewählten Bakterien aus der Probe einzufangen;
    (c) Aussetzen der magnetischen Kügelchen, an die die Erstantikörper und die eingefangenen Bakterienzellen gebunden sind, einem magnetischen Feld, um damit die magnetischen Kügelchen von der Probe abzutrennen;
    (d) Züchten der magnetischen Kügelchen und der eingefangenen Bakterienzellen auf einem festen Medium, um Kolonien der Bakterien zu bilden;
    (e) Inkontaktbringen der Kolonien mit einer Kolonie-Hub-Membran, wobei Koloniematerial dieser Kolonien an der Membran anhaftet; und
    (f) Inkontaktbringen der Membran mit Nachweisantikörpern, die an das Koloniematerial der ausgewählten Bakterien binden, und Nachweis der Gegenwart des Nachweisantikörpers auf der Membran, um einen sichtbaren Beweis für die Gegenwart des Koloniematerials der ausgewählten Bakterien auf der Membran zu liefern.
  2. Verfahren nach Anspruch 1, wobei die Membran, an der Koloniematerial anhaftet, mit Zweitantikörpern in Kontakt gebracht wird, die spezifisch für die ausgewählten Bakterien sind, wobei die Zweitantikörper an das Koloniematerial von den Kolonien der ausgewählten Bakterien binden, die Membran anschließend mit markierten Antikörpern in Kontakt gebracht wird, die spezifisch für die Zweitantikörper sind, und die Gegenwart der Markierung auf der Membran nachgewiesen wird, um damit das Vorhandensein der ausgewählten Bakterien in der Probe nachzuweisen.
  3. Verfahren nach Anspruch 1, wobei die Membran mit markierten Antikörpern in Kontakt gebracht wird, die spezifisch für die ausgewählten Bakterien sind, wobei die markierten Antikörper an das Koloniematerial der ausgewählten Bakterien binden, und die Gegenart der Markierung auf der Membran nachgewiesen wird, um damit die Gegenwart der ausgewählten Bakterien in der Probe nachzuweisen.
  4. Verfahren nach Anspruch 2 oder 3, wobei die Markierung ein fluoreszierendes, radioaktives, chemilumineszierendes, biolumineszierendes oder Enzym-Substrat-Molekül ist.
  5. Verfahren nach einem der vorstehenden Ansprüche, wobei die Erstantikörper polyclonale Antikörper gegen die ausgewählten Bakterien sind.
  6. Verfahren nach einem der Ansprüche 1 bis 5, wobei die Nachweisantikörper, Zweitantikörper und markierten Antikörper monoclonale Antikörper oder von monoclonalen Antikörpern abgeleitet sind.
  7. Verfahren nach einem der Ansprüche 2 bis 6, wobei die Markierung ein enzymatisches Molekül ist, das bei Behandlung einen Farbwechsel erzeugt, um einen sichtbaren Beweis für die Gegenwart der Markierung und Kolonien der ausgewählten Bakterien auf der Membran zu liefern.
  8. Verfahren nach Anspruch 7, wobei das enzymatische Molekül Peroxidase, alkalische Phosphatase, ·-Galactosidase, ·-Glucuronidase, ·-Glucosidase, ·-Glucosidase, ·-Mannosidase, Galactose-Oxidase, Glucose-Oxidase oder Hexokinase ist.
  9. Verfahren nach Anspruch 8, wobei die Membran mit einem chromogenen Substrat für das enzymatische Molekül behandelt wird.
  10. Verfahren nach einem der vorstehenden Ansprüche, wobei die Kolonie-Hub-Membran Nitrocellulose oder Nylon umfaßt.
  11. Verfahren nach einem der vorstehenden Ansprüche, wobei nach dem Inkontaktbringen mit den Bakterienkolonien die Membran mit einem Fixierungsmittel behandelt wird, um die Kolonien auf der Membran zu fixieren.
  12. Verfahren nach einem der vorstehenden Ansprüche, wobei die Bakterien ausgewählt sind aus Listeria, Campylobacter, Escherichia coli, Salmonella, Clostridium, Shigella, Staphylococcus, Vibrio, Yersinia, Plesiomonas strigelloides, Bacillus und Aeromonas.
  13. Verfahren nach Anspruch 12, wobei die ausgewählten Bakterien Listerien sind.
  14. Verfahren nach Anspruch 13, wobei die ausgewählten Bakterien pathogene Listerienstämme sind.
EP91107960A 1991-02-14 1991-05-16 Testverfahren zum Nachweis der Anwesenheit von Bakterien Expired - Lifetime EP0498920B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65496791A 1991-02-14 1991-02-14
US654967 1991-02-14

Publications (3)

Publication Number Publication Date
EP0498920A2 EP0498920A2 (de) 1992-08-19
EP0498920A3 EP0498920A3 (en) 1993-06-16
EP0498920B1 true EP0498920B1 (de) 2000-01-26

Family

ID=24626947

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91107960A Expired - Lifetime EP0498920B1 (de) 1991-02-14 1991-05-16 Testverfahren zum Nachweis der Anwesenheit von Bakterien

Country Status (5)

Country Link
EP (1) EP0498920B1 (de)
JP (1) JP2986961B2 (de)
AT (1) ATE189310T1 (de)
CA (1) CA2042726A1 (de)
DE (1) DE69131939D1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9434937B2 (en) 2011-03-07 2016-09-06 Accelerate Diagnostics, Inc. Rapid cell purification systems

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491068A (en) * 1991-02-14 1996-02-13 Vicam, L.P. Assay method for detecting the presence of bacteria
GB9310612D0 (en) * 1993-05-22 1993-07-07 Rhone Poulenc Diagnostics Limi New method of detection of bacteria
IES940182A2 (en) 1994-03-01 1995-11-29 Teagasc Agric Food Dev Authori "Rapid detection of bacteria in liquid cultures"
US6159689A (en) * 1995-11-10 2000-12-12 Genera Technologies Limited Methods of capture and assay procedures
WO1998045684A1 (en) * 1997-04-04 1998-10-15 Biosite Diagnostics, Inc. Methods for concentrating ligands using magnetic particles
US20020098531A1 (en) * 2001-01-25 2002-07-25 Thacker James D. Rapid methods for microbial typing and enumeration
TWI253471B (en) * 2001-01-31 2006-04-21 Food Industry Res & Dev Inst Method for rapid identification of bacillus cereus
AT412157B (de) * 2002-07-15 2004-10-25 Dsm Fine Chem Austria Gmbh Screeningmethode zum nachweis von amidase- und nitrilhydrataseaktivitäten und deren verwendung
AU2004273783A1 (en) 2003-07-12 2005-03-31 Accelr8 Technology Corporation Sensitive and rapid biodetection
US20120077206A1 (en) 2003-07-12 2012-03-29 Accelr8 Technology Corporation Rapid Microbial Detection and Antimicrobial Susceptibility Testing
US7341841B2 (en) 2003-07-12 2008-03-11 Accelr8 Technology Corporation Rapid microbial detection and antimicrobial susceptibility testing
WO2006066216A2 (en) 2004-12-16 2006-06-22 Accelr8 Technology Corporation Rapid microbial detection and antimicrobial susceptibility testing
WO2010034846A1 (es) * 2008-09-26 2010-04-01 Biótica, Bioquímica Analítica, S.L. Procedimiento rápido de detección de microorganismos con partículas magnéticas
US9201066B2 (en) 2008-09-26 2015-12-01 Biotica, Bioquimica Analitica, S.L. Rapid process for detection of microorganisms with magnetic particles
US8518658B1 (en) * 2009-04-27 2013-08-27 University Of South Florida ATP-bioluminescence immunoassay
US10254204B2 (en) 2011-03-07 2019-04-09 Accelerate Diagnostics, Inc. Membrane-assisted purification
US9677109B2 (en) 2013-03-15 2017-06-13 Accelerate Diagnostics, Inc. Rapid determination of microbial growth and antimicrobial susceptibility
US10253355B2 (en) 2015-03-30 2019-04-09 Accelerate Diagnostics, Inc. Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing
EP3278115A2 (de) 2015-03-30 2018-02-07 Accelerate Diagnostics, Inc. Instrument und system zum schnellen identifizieren von mikroorganismen und testen der antimikrobiellen wirkstoffempfindlichkeit
KR102145618B1 (ko) * 2018-12-10 2020-08-20 대한민국 면역 자성 입자를 이용한 식중독균 동시검출용 조성물 및 방법
CN112575054B (zh) * 2019-12-16 2022-12-16 中国计量科学研究院 单增李斯特菌和细菌总数快速同步多重检测方法及试剂盒
KR102351951B1 (ko) * 2020-05-06 2022-01-17 한국원자력연구원 결핵균을 검출하는 방법
WO2022154096A1 (ja) * 2021-01-15 2022-07-21 旭化成株式会社 飲食品検体、環境検体、又は生体検体中の腸内細菌科細菌の有無及び／又は存在量を検出するための方法及びキット

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE127924T1 (de) * 1987-07-28 1995-09-15 Biotech Australia Pty Ltd Nachweisverfahren.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9434937B2 (en) 2011-03-07 2016-09-06 Accelerate Diagnostics, Inc. Rapid cell purification systems

Also Published As

Publication number Publication date
DE69131939D1 (de) 2000-03-02
EP0498920A2 (de) 1992-08-19
JPH06324039A (ja) 1994-11-25
CA2042726A1 (en) 1992-08-15
JP2986961B2 (ja) 1999-12-06
EP0498920A3 (en) 1993-06-16
ATE189310T1 (de) 2000-02-15

Similar Documents

Publication Publication Date Title
EP0498920B1 (de) Testverfahren zum Nachweis der Anwesenheit von Bakterien
CA2112603C (en) Assay method for detecting the presence of bacteria
US5648227A (en) Method of detecting microorganisms
US5004699A (en) Method to detect fungi and yeasts
CA2190109C (en) Compositions and methods for control of reactivity between diagnostic reagents and microorganisms
JP2779509B2 (ja) 検出方法
US5168037A (en) Method for the preparation of a labelled virus without the inactivation of viral binding sites and method of assay utilizing said labelled virus
US20110020861A1 (en) Method for the real-time detection of microorganisms in a liquid culture medium by agglutination
EP1068532A1 (de) Realzeit-detektion von antikörpern
JPH04503754A (ja) モノクローナル抗体に基づくリステリア・モノシトゲネスの検出システムの開発
US6531278B1 (en) Ligand-DNA composition for capture and detection of contaminants on a solid surface
JP3773633B2 (ja) 大腸菌ｏ１５７の分析方法及び分析用試薬
US7241626B2 (en) Isolation and confirmation of analytes from test devices
WO1992017786A1 (en) Assay device and method of detecting chitin
JPS62276465A (ja) 淋病および髄膜炎の診断方法および試薬
JP3614779B2 (ja) ビール有害乳酸菌検出用抗体とその診断的用途
Bernal et al. Development of a sensitive and quantitative enzyme-linked immunofilter assay (ELIFA) for whole bacterial cells
JPWO2002065131A1 (ja) ビブリオ属細菌の検出法および検出用試薬ならびにこれらに使用する抗体
RU2737776C1 (ru) Тест-комплект для выявления холерного токсина в среде культивирования
JP2001004631A (ja) 磁気ビーズ固定化抗体を用いた微生物の迅速検定法
Waitkins et al. The detection and enumeration of Leptospira interrogans serovar hardjo by time-resolved fluoroimmunoassay
NO173714B (no) Fremgangsmaate for kvalitativ og kvantitativ bestemmelse av speisielle antigener, spesielt sporer av clostridium tyrobutyricum
JPH06213894A (ja) 水中のレジオネラ菌の検出方法
WO1998013692A1 (en) Microorganism separation system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19931202

17Q First examination report despatched

Effective date: 19960308

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRE;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.SCRIBED TIME-LIMIT

Effective date: 20000126

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000126

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000126

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000126

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000126

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000126

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000126

Ref country code: SE

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 20000126

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 20000126

Ref country code: FR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000126

REF Corresponds to:

Ref document number: 189310

Country of ref document: AT

Date of ref document: 20000215

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69131939

Country of ref document: DE

Date of ref document: 20000302

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000427

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000516

EN Fr: translation not filed
NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20091015 AND 20091021

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20100525

Year of fee payment: 20

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20110515

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20110515